Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer

Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer

(2019) Elena Rangelova et al.   ANNALS OF SURGERY

Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer

(2019) Mark J. Truty et al.   ANNALS OF SURGERY

Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer

(2019) Janet E. Murphy et al.   JAMA Oncology

671OConversion rate in locally advanced pancreatic cancer (LAPC) after nab-paclitaxel/gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP): Final results of a multicenter randomised phase II AIO trial

(2019) V Kunzmann et al.   ANNALS OF ONCOLOGY

Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection

(2018) Georgios Gemenetzis et al.   ANNALS OF SURGERY

Interim results of a multicenter phase II trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients (Pts) with locally advanced pancreatic cancer (LAPC).

(2017) Jill Lacy et al.   JOURNAL OF CLINICAL ONCOLOGY

Positron emission tomography response evaluation from a randomized phase III trial of weeklynab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

(2016) R. K. Ramanathan et al.   ANNALS OF ONCOLOGY

CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weeklynab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer

(2016) E. G. Chiorean et al.   ANNALS OF ONCOLOGY

Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib

(2016) Pascal Hammel et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis

(2016) Mustafa Suker et al.   LANCET ONCOLOGY

Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer

(2015) Cristina R. Ferrone et al.   ANNALS OF SURGERY

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

(2014) L. Rahib et al.   CANCER RESEARCH

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer

(2013) R Alvarez et al.   BRITISH JOURNAL OF CANCER

CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer

(2013) A. Neesse et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Could Aging Human Skin Use a Connective Tissue Growth Factor Boost to Increase Collagen Content?

(2010) Noelynn Oliver et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Pancreatic Cancer

(2010) Manuel Hidalgo   NEW ENGLAND JOURNAL OF MEDICINE

Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages

(2010) Sonja Gillen et al.   PLOS MEDICINE